机构：[a]Department of Neurology, West China Hospital, Sichuan University, Chengdu, China[b]Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China[c]State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China[d]Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK[e]Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[f]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[g]Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China神经内科神经疾病高创中心（北京学者工作室）[h]Faculty of Rehabilitation Medicine, Capital Medical University, Beijing, China[i]Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China神经外科[j]Neurorehabilitation Department, China Rehabilitation Research Center, Beijing, China[k]The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia[l]The George Institute China at Peking University Health Science Center, Beijing, China[m]Neurology Department, Royal Prince Alfred Hospital, Sydney, NSW, Australia[n]Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK[o]Department of Neurology, Peking University First Hospital, Beijing, China[p]Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China[q]Department of Neurology, Chinese PLA General Hospital, Beijing, China[r]Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China[s]Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China[t]Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China[u]Department of Neurology, Peking University Third Hospital, Beijing, China[v]Key Laboratory for Neuroscience, Ministry of Education/National Health Commission, Peking University, Beijing, China[w]Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China[x]Stroke Prevention Project Committee of National Health Commission of the People's Republic of China, Beijing, China
With over 2 million new cases annually, stroke is associated with the highest disability-adjusted life-years lost of any disease in China. The burden is expected to increase further as a result of population ageing, an ongoing high prevalence of risk factors (eg, hypertension), and inadequate management. Despite improved access to overall health services, the availability of specialist stroke care is variable across the country, and especially uneven in rural areas. In-hospital outcomes have improved because of a greater availability of reperfusion therapies and supportive care, but adherence to secondary prevention strategies and long-term care are inadequate. Thrombolysis and stroke units are accepted as standards of care across the world, including in China, but bleeding-risk concerns and organisational challenges hamper widespread adoption of this care in China. Despite little supporting evidence, Chinese herbal products and neuroprotective drugs are widely used, and the increased availability of neuroimaging techniques also results in overdiagnosis and overtreatment of so-called silent stroke. Future efforts should focus on providing more balanced availability of specialised stroke services across the country, enhancing evidence-based practice, and encouraging greater translational research to improve outcome of patients with stroke.
第一作者机构：[a]Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
共同第一作者：
通讯作者：
通讯机构：[a]Department of Neurology, West China Hospital, Sichuan University, Chengdu, China[*1]Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China[b]Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu, China[c]State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
推荐引用方式(GB/T 7714)：
Simiao Wu,Bo Wu,Ming Liu,et al.Stroke in China: advances and challenges in epidemiology, prevention, and management[J].LANCET NEUROLOGY.2019,18(4):394-405.doi:10.1016/S1474-4422(18)30500-3.
APA：
Simiao Wu,Bo Wu,Ming Liu,Zhengming Chen,Wenzhi Wang...&Longde Wang.(2019).Stroke in China: advances and challenges in epidemiology, prevention, and management.LANCET NEUROLOGY,18,(4)
MLA：
Simiao Wu,et al."Stroke in China: advances and challenges in epidemiology, prevention, and management".LANCET NEUROLOGY 18..4(2019):394-405
医学